SCHEMBL27201439

SCHEMBL27201439

CN(C)CCNC(=O)c1cc2cc(-c3ccc4ccnc(N)c4c3)ccc2cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.45
PRKD1 Q15139 1/20 0.45
PRKD2 Q9BZL6 1/20 0.45
BRAF P15056 1/20 0.44
WNT1 P04628 3/20 0.43
DYRK1A Q13627 3/20 0.43
CLK2 P49760 2/20 0.42
CLK3 P49761 2/20 0.42
GSK3B P49841 2/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
CHEK2 O96017 1/20 0.42
MAP4K4 O95819 3/20 0.41
HDAC2 Q92769 1/20 0.41
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
TYK2 P29597 1/20 0.40
JAK3 P52333 1/20 0.40
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30885290 1.00 PRKD3 (0.45) PRKD3PRKD1PRKD2BRAFWNT1
SCHEMBL27201405 0.79 DYRK1A (0.67) WNT1DYRK1ACLK2CLK3GSK3B
SCHEMBL30834220 0.79 RAD52 (0.42) PRKD3PRKD1PRKD2WNT1DYRK1A
SCHEMBL27201530 0.79 RAD52 (0.42) PRKD3PRKD1PRKD2WNT1DYRK1A
SCHEMBL30834224 0.79 RAD52 (0.42) PRKD3PRKD1PRKD2WNT1DYRK1A
SCHEMBL27201334 0.79 CHEK2 (0.50) PRKD3PRKD1PRKD2WNT1DYRK1A
SCHEMBL30834169 0.78 CHEK2 (0.47) PRKD3PRKD1PRKD2BRAFWNT1
SCHEMBL27201601 0.78 CHEK2 (0.47) PRKD3PRKD1PRKD2BRAFWNT1
SCHEMBL30885239 0.78 CHUK (0.56) PRKD3PRKD1PRKD2WNT1DYRK1A
SCHEMBL27201568 0.78 CHUK (0.56) PRKD3PRKD1PRKD2WNT1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP PRKD3 515/4885PRKD1 341/4885PRKD2 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.